MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2024 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Depreciation & Amortization (CF) of $800000.0 for Q1 2026, up 111.64% year-over-year from $378000.0 in Q1 2025, and up 11.73% quarter-over-quarter from $716000.0 in Q4 2025.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 111.64% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $3.0 million (up 109.52% YoY), while the FY2025 annual figure was $2.6 million, up 86.86% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $800000.0, up from $716000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $800000.0 in Q3 2025, with the low at $2488.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $321000.0 (2024), against an average of $284795.1.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) plunged 33.84% in 2022, then soared 11423.26% in 2024.
- MoonLake Immunotherapeutics' Depreciation & Amortization (CF) stood at $3289.0 in 2022, then changed by 0.0% to $3289.0 in 2023, then jumped by 11423.26% to $379000.0 in 2024, then jumped by 88.92% to $716000.0 in 2025, then rose by 11.73% to $800000.0 in 2026.
- Business Quant data shows MLTX's Depreciation & Amortization (CF) at $800000.0 in Q1 2026, $716000.0 in Q4 2025, and $800000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.11 Bn | 572.81 Mn | - | 896,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 896,000.00 |
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 716,000.00 |
| Sep 30, 2025 | 780,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 379,000.00 |
| Sep 30, 2024 | 321,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Mar 31, 2024 | 328,000.00 |